Pfizer (PFE) Acquisitions (2009 - 2023)

Pfizer (PFE) reported Acquisitions of $43.4 billion for Q4 2023, up 173520.0% quarter-over-quarter from $25.0 million in Q3 2023.

Pfizer (PFE) Acquisitions (2009 - 2023) Analysis & Trends

Pfizer (PFE) has 10 years of Acquisitions data on file, last reported at $43.4 billion in Q4 2023.

Acquisitions for Q4 2023 came in at $43.4 billion, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was $43.4 billion (up 594.88% YoY), and the FY2025 annual result was $6.9 billion, changed N/A from the prior year.
Acquisitions climbed to $43.4 billion in Q4 2023 per PFE's latest filing, from $25.0 million in the prior quarter.
Over five years, Acquisitions peaked at $43.4 billion in Q4 2023 and troughed at $25.0 million in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Gsk	92,316,836.42 Bn	92,316,831.46 Bn	7.76 Bn	-1.89 Bn
2	Eli Lilly	983.57 Bn	978.29 Bn	16.22 Bn	-
3	Johnson & Johnson	553.56 Bn	531.50 Bn	15.96 Bn	-
4	AbbVie	383.35 Bn	374.00 Bn	10.78 Bn	-
5	Merck	281.71 Bn	276.06 Bn	12.09 Bn	8.78 Bn
6	Amgen	182.20 Bn	170.16 Bn	5.87 Bn	-
7	Gilead Sciences	153.71 Bn	145.98 Bn	5.52 Bn	109.00 Mn
8	Pfizer	143.75 Bn	130.98 Bn	-1.21 Bn	-
9	Bristol Myers Squibb	109.71 Bn	99.25 Bn	8.07 Bn	65.00 Mn
10	Novartis Ag	108.28 Bn	107.60 Bn	-	-

Download Data